Chk1, Checkpoint Kinase 1
Results may vary from person to person depending upon age, sex, basal metabolic rate, medical history, family history, lifestyle and physical activity
Unlike traditional growth hormone therapy, AOD-9604 does not significantly increase insulin-like growth factor-1 (IGF-1) or disrupt normal hormone levels
Basically, it tells certain genes to turn on or off, encouraging your cells to regenerate and heal faster
If GHK-Cu is not bioavailable orally, its benefits might be limited to topical or injectable forms
At baseline, eGFR was 90 mL/min/1.73 m2 in 43%, 60 to 90 mL/min/1.73 m2 in 40%, 45 to 60 mL/min/1.73 m2 in 10%, and 30 to 45 mL/min/1.73 m2 in 6% of patients